Neddylation Blockade Potentiates Camptothecin Nanotherapy for Synergistic Topoisomerase I Inhibition in Advanced Colorectal Cancer

Abstract Camptothecin (CPT) is a potent Topoisomerase I (TOP1) inhibitor that induces DNA damage through the formation of TOP1-DNA–protein cross-links (TOP1-DPCs). Despite its promising anticancer activity, the clinical translation of CPT has been limited by lactone instability, rapid clearance, off-target toxicities, and unfavorable pharmacokinetics. To overcome these limitations, we previously developed Camptothesome, a sphingomyelin-conjugated CPT nanovesicle that stabilizes the active lactone form of CPT, prolongs circulation, enhances tumor accumulation, and improves therapeutic efficacy against colorectal cancer (CRC). However, cancer cells can repair TOP1-DPCs through a neddylation-dependent pathway, reducing their sensitivity to CPT. To address this mechanism, we developed C-pevosome, a dual-drug liposomal nanoplatform that codelivers CPT and the NEDD8-activating enzyme inhibitor pevonedistat (PEV) at an optimized synergistic ratio. By simultaneously inducing TOP1-DPC formation and blocking neddylation-mediated repair, C-pevosome enhanced DNA damage, apoptosis, tumor accumulation, and antitumor efficacy while reducing systemic toxicity. To further improve intratumoral delivery, we engineered AzC-pevosome by incorporating a tumor-acidic pH-responsive charge-reversal phospholipid, which promoted cellular uptake, tumor penetration, and intratumoral distribution. Consequently, AzC-pevosome further enhanced therapeutic efficacy and sensitized tumors to immune checkpoint blockade, resulting in superior tumor suppression in advanced orthotopic CRC models. This strategy holds strong potential to improve therapeutic efficacy, safety, and patient compliance in CRC treatment.

Authors

Institutions

Publication Details

Journal
ACS Nano Medicine
Published
2026-11-12
DOI
https://doi.org/10.1021/acsnanomed.6c00154
Primary Topic
Cancer therapeutics and mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Neddylation Blockade Potentiates Camptothecin Nanotherapy for Synergistic Topoisomerase I Inhibition in Advanced Colorectal Cancer

Yanhao Jiang, Leyla Estrella Cordova, Wenpan Li, Jianqin Lu et al.
ACS Nano Medicine
Cancer therapeutics and mechanisms
article

Neddylation Blockade Potentiates Camptothecin Nanotherapy for Synergistic Topoisomerase I Inhibition in Advanced Colorectal Cancer

Yanhao Jiang, Leyla Estrella Cordova, Wenpan Li, Jianqin Lu, Mengwen Li, Elliott Brumbaugh
article en

Abstract

Abstract Camptothecin (CPT) is a potent Topoisomerase I (TOP1) inhibitor that induces DNA damage through the formation of TOP1-DNA–protein cross-links (TOP1-DPCs). Despite its promising anticancer activity, the clinical translation of CPT has been limited by lactone instability, rapid clearance, off-target toxicities, and unfavorable pharmacokinetics. To overcome these limitations, we previously developed Camptothesome, a sphingomyelin-conjugated CPT nanovesicle that stabilizes the active lactone form of CPT, prolongs circulation, enhances tumor accumulation, and improves therapeutic efficacy against colorectal cancer (CRC). However, cancer cells can repair TOP1-DPCs through a neddylation-dependent pathway, reducing their sensitivity to CPT. To address this mechanism, we developed C-pevosome, a dual-drug liposomal nanoplatform that codelivers CPT and the NEDD8-activating enzyme inhibitor pevonedistat (PEV) at an optimized synergistic ratio. By simultaneously inducing TOP1-DPC formation and blocking neddylation-mediated repair, C-pevosome enhanced DNA damage, apoptosis, tumor accumulation, and antitumor efficacy while reducing systemic toxicity. To further improve intratumoral delivery, we engineered AzC-pevosome by incorporating a tumor-acidic pH-responsive charge-reversal phospholipid, which promoted cellular uptake, tumor penetration, and intratumoral distribution. Consequently, AzC-pevosome further enhanced therapeutic efficacy and sensitized tumors to immune checkpoint blockade, resulting in superior tumor suppression in advanced orthotopic CRC models. This strategy holds strong potential to improve therapeutic efficacy, safety, and patient compliance in CRC treatment.

ACS Nano Medicine
University of Arizona (US), University of Arizona Cancer Center (US)
Pharmaceutical Research and Manufacturers of America Foundation, University of Arizona Cancer Center, National Cancer Institute, National Institute of General Medical Sciences
Good health and well-being
Cancer therapeutics and mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon